Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

J. K. Hicks, J. J. Swen, C. F. Thorn, K. Sangkuhl, E. D. Kharasch, V. L. Ellingrod, T. C. Skaar, D. J. Müller, A. Gaedigk, J. C. Stingl

Research output: Contribution to journalArticle

271 Citations (Scopus)

Abstract

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

Original languageEnglish (US)
Pages (from-to)402-408
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume93
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Cytochrome P-450 CYP2D6
Tricyclic Antidepressive Agents
Pharmacogenetics
Genotype
Guidelines
Trimipramine
Doxepin
Nortriptyline
Clomipramine
Desipramine
Amitriptyline
Imipramine
Hydroxylation
Pharmaceutical Preparations
Safety
Cytochrome P-450 CYP2C19
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. / Hicks, J. K.; Swen, J. J.; Thorn, C. F.; Sangkuhl, K.; Kharasch, E. D.; Ellingrod, V. L.; Skaar, T. C.; Müller, D. J.; Gaedigk, A.; Stingl, J. C.

In: Clinical Pharmacology and Therapeutics, Vol. 93, No. 5, 01.05.2013, p. 402-408.

Research output: Contribution to journalArticle

Hicks, JK, Swen, JJ, Thorn, CF, Sangkuhl, K, Kharasch, ED, Ellingrod, VL, Skaar, TC, Müller, DJ, Gaedigk, A & Stingl, JC 2013, 'Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants', Clinical Pharmacology and Therapeutics, vol. 93, no. 5, pp. 402-408. https://doi.org/10.1038/clpt.2013.2
Hicks, J. K. ; Swen, J. J. ; Thorn, C. F. ; Sangkuhl, K. ; Kharasch, E. D. ; Ellingrod, V. L. ; Skaar, T. C. ; Müller, D. J. ; Gaedigk, A. ; Stingl, J. C. / Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. In: Clinical Pharmacology and Therapeutics. 2013 ; Vol. 93, No. 5. pp. 402-408.
@article{6b21adfcbc1a4e37b6b782587a0630c3,
title = "Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants",
abstract = "Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.",
author = "Hicks, {J. K.} and Swen, {J. J.} and Thorn, {C. F.} and K. Sangkuhl and Kharasch, {E. D.} and Ellingrod, {V. L.} and Skaar, {T. C.} and M{\"u}ller, {D. J.} and A. Gaedigk and Stingl, {J. C.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1038/clpt.2013.2",
language = "English (US)",
volume = "93",
pages = "402--408",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

AU - Hicks, J. K.

AU - Swen, J. J.

AU - Thorn, C. F.

AU - Sangkuhl, K.

AU - Kharasch, E. D.

AU - Ellingrod, V. L.

AU - Skaar, T. C.

AU - Müller, D. J.

AU - Gaedigk, A.

AU - Stingl, J. C.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

AB - Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

UR - http://www.scopus.com/inward/record.url?scp=84876665512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876665512&partnerID=8YFLogxK

U2 - 10.1038/clpt.2013.2

DO - 10.1038/clpt.2013.2

M3 - Article

C2 - 23486447

AN - SCOPUS:84876665512

VL - 93

SP - 402

EP - 408

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -